succinobucol has been researched along with tbc-11251 in 1 studies
| Studies (succinobucol) | Trials (succinobucol) | Recent Studies (post-2010) (succinobucol) | Studies (tbc-11251) | Trials (tbc-11251) | Recent Studies (post-2010) (tbc-11251) |
|---|---|---|---|---|---|
| 53 | 5 | 16 | 167 | 32 | 58 |
| Protein | Taxonomy | succinobucol (IC50) | tbc-11251 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 4.9049 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biswal, S | 1 |
1 other study(ies) available for succinobucol and tbc-11251
| Article | Year |
|---|---|
Novel cardiovascular drugs in clinical trials.
Topics: Anticholesteremic Agents; Benzaldehydes; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrinolytic Agents; Humans; Immunologic Factors; Isoxazoles; Lipoxygenase Inhibitors; Metalloendopeptidases; Oxazolidinones; Oximes; Phospholipase A2 Inhibitors; Probucol; Pyrimidines; Quinolines; Thiophenes | 2010 |